- Home
- BMEA vs IAE Comparison
BMEA vs IAE Comparison
Compare BMEA & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMEA | IAE |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5M | 80.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BMEA | IAE |
|---|---|---|
| Price | $1.43 | $7.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.71 | N/A |
| AVG Volume (30 Days) | ★ 767.7K | 61.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.21% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $5.30 |
| 52 Week High | $3.08 | $8.30 |
Technical Indicators
Market Signals| Indicator | BMEA | IAE |
|---|---|---|
| Relative Strength Index (RSI) | 56.24 | 29.81 |
| Support Level | $1.24 | $7.11 |
| Resistance Level | $1.43 | $7.56 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 66.67 | 8.36 |
Price Performance
Historical ComparisonAbout BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.